RxDoctor Payments Data

Kathleen Sterling, MD

Urology · Bethesda, MDNPI 1003041765

Payments from drug & device makers

$8,116in general payments, 2019–2025

Across 291 payments — averaging $27.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Teleflex LLC$1K
  • AbbVie$1K
  • Astellas Pharma US Inc$370
  • Sumitomo Pharma America, Inc.$298
  • Progenics Pharmaceuticals, Inc.$292
  • plus $3K from 38 others

What the payments were for

  • Speaking & faculty fees$4736%
  • Food & beverage$7,60894%
  • Education$350%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,116 in reported general payments places this provider in the 60th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$446,577
Medicare patients
1,022
Services billed
18,772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron383$389,149
MyrbetriqMirabegron165$152,214
Methenamine Hippurate189$14,118
Estradiol177$12,371
PremarinEstrogens, Conjugated17$7,136
Tamsulosin Hcl273$4,730
Fosfomycin Tromethamine18$2,906
Potassium Citrate ErPotassium Citrate28$2,272
Solifenacin Succinate40$2,017
NitrofurantoinNitrofurantoin Macrocrystal56$1,867
Trospium Chloride ErTrospium Chloride12$1,713
Dutasteride23$1,566
Alfuzosin Hcl ErAlfuzosin Hcl55$1,259
Finasteride82$1,036
Cephalexin55$884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$298$389,149383 claims
Astellas Pharma US IncMyrbetriq$370$152,214165 claims
PfizerPremarin$202$7,13617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 274 urology providers in Maryland.

Other urology in Bethesda

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →